Banca de DEFESA: GABRIEL SALERNO COSTA

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : GABRIEL SALERNO COSTA
DATE: 31/08/2022
TIME: 08:00
LOCAL: meet.google.com/rda-ktpk-nmy
TITLE:

EFFECT OF ATORVASTATIN ON BLOOD PRESSURE AND ITS AUTONOMIC MODULATION IN HUMANS AND RODENTS: A SYSTEMATIC REVIEW WITH META-ANALYSIS

KEY WORDS:

Atorvastatin. Autonomic modulation. Blood pressure.

PAGES: 85
BIG AREA: Ciências Biológicas
AREA: Bioquímica
SUMMARY:

Atorvastatin is a drug commonly used to reduce the cholesterol synthesis in hypercholesterolemia treatment by inhibiting HMG-CoA reductase. More recently, studies have shown that statins, in addition to their lipid-lowering action, potentially affect the autonomic nervous system (ANS), prevent cardiac dysfunction by inhibiting oxidative stress and improving endothelial function. This study aimed to evaluate, through a systematic review with meta-analysis, the atorvastatin effect on blood pressure and its autonomic modulation, as well as to clarify, through meta-regression, the relationship between these effects and cholesterol changes. Using Pubmed database, we selected primary studies that analyzed the atorvastatin effect on blood pressure, heart rate, baroreflex and/or heart rate variability (HRV) in randomized clinical and preclinical studies performed in mammals. Included articles were stratified according to baseline characteristics of the population and their methodological quality was assessed using the Jadad or SYRCLE scale. Independent statistical analyzes were performed for each parameter for clinical and preclinical studies considering all included articles and/or each stratification. In clinical trials, our meta-analysis showed that atorvastatin reduces systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) when compared to baseline and/or placebo in hyperlipidemic individuals with or without hypertension. Atorvastatin did not affect the HRV and the baroreflex. Although the meta-regression of all primary articles demonstrates that the effect of atorvastatin in reducing SBP and DBP is associated with a reduction in LDL compared to baseline, this association is not observed when compared to placebo. In preclinical studies, compared to control, atorvastatin does not affect SBP in rats fed a control diet and spontaneously hypertensive-stroke prone rats, but reduces SBP in rats fed a high salt diet (4%), hyperlipidemic, diabetics and hypertensive rats by renal surgery or spontaneously hypertensive (SHR) rats. The effect of atorvastatin in reducing SBP in SHR rats is not associated with a reduction in LDL or total cholesterol, showing that SBP reduction is independent of lipid changes. Thus, our systematic review with meta-analysis demonstrated that the cardiovascular effect of atorvastatin occurs independently of the reduction in total and/or LDL cholesterol and of ANS modulation.

BANKING MEMBERS:
Interno - 1367304 - ALEXSANDRO SOBREIRA GALDINO
Externa à Instituição - ANA MARIA CLARK PERES - UFMG
Interna - 1716801 - CRISTIANE QUEIXA TILELLI
Presidente - 1692875 - VALERIA ERNESTANIA CHAVES